Benzinga | Jun 14, 2021 09:00AM EDT

JonesTrading Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces Price Target of $8

JonesTrading analyst Prakhar Agrawal initiates coverage on CymaBay Therapeutics (NASDAQ:CBAY) with a Buy rating and announces Price Target of $8.